No News On Valsartan Approval But Ranbaxy Keeps Sales Guidance Unchanged
This article was originally published in PharmAsia News
Executive Summary
The Indian drug manufacturer is trying to come out of the long shadow of U.S. FDA investigations, but the repercussions continue to afflict its prospects in the U.S. market.